Related sites
الخط الساخن للخدمات الصحية للنازحين اللبنانيين 1787   
الخط الساخن لدخول المرضى الى المستشفيات 01/832700   
التسجيل لأخذ لقاح الكورونا covax.moph.gov.lb   
الخط الساخن لوزارة الصحّة العامة 1214   
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

رؤية الوزارة حول التحول الرقمي للقطاع الصحي


Foreword by the Minister of Health

In the following pages, we reveal a compelling vision for the future of digital health in Lebanon—an innovative blueprint developed through collaborative, forward-thinking, and inclusive efforts. With the recognition of digital technology as an integral driver of healthcare improvement, the Ministry of Public Health (MoPH) has been at the forefront, rallying essential stakeholders and orchestrating strategic discussions aimed at redefining our healthcare landscape.

This grand vision is grounded in the National Health Strategy, launched by the MoPH in January 2023. Recognizing the importance of digital health transformation, this strategy identified it as a crucial pillar. From this sturdy foundation, the Digital Health Retreat was organized on May 18, 2023. This retreat acted as a catalyst, creating an arena for stakeholders to identify the challenges and opportunities present in Lebanon's digital health ecosystem. A consensus was reached, emphasizing the pressing need for a consolidated vision that enables our healthcare system and augments health outcomes for our people.

Our healthcare sector, while resilient, faces its fair share of hurdles. With this understanding, and building upon the significant investments in digital health stipulated by the National Health Strategy, our vision aims to utilize digital solutions to overcome these barriers, thereby enriching healthcare outcomes. This is a vision of synergy, empowerment, and readiness for the evolving landscape of healthcare.

Our transformative vision transcends policy constraints. It establishes a detailed blueprint for developing a resilient digital health infrastructure. These strategies encompass a multitude of aspects—from digital platforms and mobile applications to health information exchange systems and more.
The implications of this digital health transformation are immense. From improved care coordination to enhanced population health outcomes, this vision for digital health, inherent in the National Health Strategy, is poised to serve as a guiding beacon for our future. Our journey begins here, and we invite you to join us as we map the pathway for a healthier Lebanon. Together, we can transform this vision into reality.

Vision for Digital Health Transformation
    ...
    148
    ...
ATC Name B/G Ingredients Dosage Form Price
P02CA01 VERMOX B Mebendazole - 500mg 500mg Tablet 106,164 L.L
V03AC03 JADENU B Deferasirox - 180mg 180mg Tablet, film coated 27,151,164 L.L
A07EC02 ASACOL B Mesalazine - 1g/100ml 1g/100ml Enema 2,748,158 L.L
A10BX16 MOUNJARO KWIKPEN B Tirzepatide - 10mg/dose 10mg/dose Injectable solution 39,601,065 L.L
C10AA07 CRESTOR B Rosuvastatin (calcium) - 10mg 10mg Tablet, film coated 804,962 L.L
J07AL01 PNEUMOVAX 23 B Polysaccharides from each of 23 capsular types of Streptococcus pneumoniae - 25mcgx23serotypes/0.5ml Injectable solution 2,378,601 L.L
N03AX11 TOPAMAX 25 B Topiramate - 25mg 25mg Tablet, film coated 858,715 L.L
P02CA01 VERMOX B Mebendazole - 100mg 100mg Tablet 190,826 L.L
A07EC02 PENTASA B Mesalazine - 1g 1g Enema 2,791,161 L.L
A10BX16 MOUNJARO KWIKPEN B Tirzepatide - 12.5mg/dose 12.5mg/dose Injectable solution 39,601,065 L.L
J07AL02 PREVENAR 13 B Polysaccharide for serotypes 1, 3, 4, 5 , 6A, 7F, 9V,14, 18C, 19A, 19F, 23F (2.2mcg)Polysaccharide for serotypes 6B (4.4mcg)Conjugated to CRM197 carrier protein and adsorbed on aluminium phosphate (0.125mg aluminium) - Injectable suspension 6,352,343 L.L
M01AB16 AIRTAL 100MG 20 B Aceclofenac - 100mg 100mg Tablet, film coated 471,689 L.L
R05X ACTISOUFRE B Sulfure de Sodium - 13mg, Saccharomyces Cerevisiae - 500mg Solution 740,457 L.L
A07EC02 SALOFALK B Mesalazine - 1.5g 1.5g Granules, gastro-resistant, prolonged release 6,150,767 L.L
A10BX16 MOUNJARO KWIKPEN B Tirzepatide - 15mg/dose 15mg/dose Injectable solution 39,601,065 L.L
C03EA01 MODURETIC B Hydrochlorothiazide - 50mg, Amiloride HCl - 5mg Tablet 798,398 L.L
D10AD03 DIFFERIN B Adapalene - 0.1g/100g 0.1% Cream 521,411 L.L
J07AL02 SYNFLORIX B Polysaccharide from each of 10 capsular types of pneumococcus (conjugated to carrier proteins) adsorbed onto aluminium phosphate - 1mcg/0.5ml, Polysaccharide of serotypes 41,2, 18C1,3 and 19F1,4 - 3mcg/0.5ml, 1 adsorbed onto aluminium phosphate - 0.5mg Al3+, 2 conjugated to protein D (derived from NTHi) carrier protein - ~ 13mcg, 3 conjugated to tetanos toxoid carrier protein - ~ 8mcg, 4 conjugated to diphteria toxoid carrier protein - ~ 5mcg Injectable suspension 4,675,228 L.L
L01ED01 XALKORI B Crizotinib - 250mg 250mg Capsule 347,644,061 L.L
R05X FERVEX CHILDREN SUGAR FREE B Paracetamol - 280mg, Ascorbic acid - 100mg, Pheniramine maleate - 10mg Granules for solution 425,998 L.L
V03AC03 JADENU B Deferasirox - 360mg 360mg Tablet, film coated 27,151,500 L.L
A07EC02 SALOFALK B Mesalazine - 3g 3g Granules, gastro-resistant, prolonged release 11,256,652 L.L
C09CA04 APROVEL B Irbesartan - 300mg 300mg Tablet, film coated 651,764 L.L
L01ED01 XALKORI B Crizotinib - 200mg 200mg Capsule 347,644,061 L.L
N03AX11 TOPAMAX B Topiramate - 50mg 50mg Tablet, film coated 1,914,976 L.L
R05X FERVEX ADULTS SUGAR FREE B Paracetamol - 500mg, Ascorbic acid - 200mg, Pheniramine maleate - 25mg Granules for solution 425,998 L.L
A07EC02 ASACOL B Mesalazine - 1600mg 1600mg Tablet, modified release 8,454,523 L.L
C04AX21 NAFTILUX B Naftidrofuryl oxalate acid - 200mg 200mg Capsule 432,717 L.L
C09CA04 APROVEL B Irbesartan - 300mg 300mg Tablet, film coated 651,764 L.L
D10AD03 DIFFERIN B Adapalene - 0.1g/100g 0.1% Gel 503,941 L.L
    ...
    148
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025